The efficacy and safety of activated vitamin D for CKD-MBD

Nobuki Hayakawa, Atsushi Suzuki

Research output: Contribution to journalArticle

Abstract

Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.

Original languageEnglish
Pages (from-to)1333-1338
Number of pages6
JournalClinical calcium
Volume26
Issue number9
Publication statusPublished - 01-09-2016

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this